Literature DB >> 19212119

Treatment of melanoma metastases confined to the liver and future perspectives.

Alexander L Vahrmeijer1, Cornelis J H van de Velde, Henk H Hartgrink, Rob A E M Tollenaar.   

Abstract

The prognosis for patients with liver metastases derived from melanoma is very poor. Although being the gold standard for colorectal metastases, hepatic resection for melanoma lesions is rarely possible. For patients with liver metastases from cutaneous melanoma, the liver is not the only site of disseminated disease in the majority of the cases. Most experience has been obtained in patients with liver metastases from uveal melanoma because in 40% of these patients, the liver is the only site of disease. However, in these patients, resection is frequently not possible due to the number and localization of the metastases. Results from systemic chemotherapy are poor and therefore, in order to increase response rate, regional treatment modalities like hepatic artery infusion, isolated hepatic perfusion and hepatic arterial chemoembolization can be considered. In this review, we will describe the various treatment modalities as well as new developments. (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19212119     DOI: 10.1159/000184738

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  8 in total

1.  Two cases of partial hepatectomy for malignant melanoma.

Authors:  Aaron I Karlen; Justin J Clark; Linda L Wong
Journal:  Hawaii J Med Public Health       Date:  2012-04

2.  Complete resection of isolated hepatic metastatic uveal melanoma with a notably long disease-free period: A case report and review of the literature.

Authors:  Shengzhang Lin; Dalong Wan; Haiyong Chen; Kangjie Chen; Shusen Zheng
Journal:  Oncol Lett       Date:  2015-05-18       Impact factor: 2.967

Review 3.  Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets.

Authors:  Adam J Kimple; Dustin E Bosch; Patrick M Giguère; David P Siderovski
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

4.  First experience on laparoscopic near-infrared fluorescence imaging of hepatic uveal melanoma metastases using indocyanine green.

Authors:  Quirijn R J G Tummers; Floris P R Verbeek; Hendrica A J M Prevoo; Andries E Braat; Coen I M Baeten; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer
Journal:  Surg Innov       Date:  2014-06-05       Impact factor: 2.058

5.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

6.  Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver.

Authors:  Eleonora M de Leede; Mark C Burgmans; Christian H Martini; Fred G J Tijl; Arian R van Erkel; Jaap Vuyk; Ellen Kapiteijn; Cornelis Verhoef; Cornelis J H van de Velde; Alexander L Vahrmeijer
Journal:  J Vis Exp       Date:  2016-07-31       Impact factor: 1.355

Review 7.  Proteomics of uveal melanoma: a minireview.

Authors:  Søren K O Abildgaard; Henrik Vorum
Journal:  J Oncol       Date:  2013-09-03       Impact factor: 4.375

8.  Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis.

Authors:  Minsu Lee; Song-Ee Baek; Jieun Moon; Yun Ho Roh; Joon Seok Lim; Mi-Suk Park; Myeong-Jin Kim; Honsoul Kim
Journal:  Oncotarget       Date:  2016-06-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.